Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotech Is up 181% This Year; Here's Why It Can Still Go Higher - Barron's
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales - Yahoo Sports
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock
Puma Biotech (PBYI) Stock Jumps 10.0%: Will It Continue to Soar?
Puma Biotech Surges, Defying Yellen
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Defies Odds, Wins FDA Backing for Breast Cancer Drug | BioSpace
Articles about Puma Biotechnology
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High | Investor's Business Daily
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotech's Overnight Billionaire On One Of His Keys To Success
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech plunges on drug side effects
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
